Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | The current challenges facing high-risk MDS treatment

Lionel Ades, MD, PhD, Avicenne Hospital, Bobigny, France, outlines the current challenges facing high-risk myelodysplastic syndromes (MDS) treatment. Specifically discussed is improving the results of hypomethylating agents such as azacitidine with other agents and the subsequent issue of side effects. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).